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                                                                                 ABSTRACT 
 “COGNITIVE PROFILE IN RENAL TRANSPLANT RECIPIENTS” 
     N.SHANKAR GANESH 1, PROF. DR. R.LAKSHMI NARASIMHAN, 2       
DR.S.GOPALAKRISHNAN, 3 
Aim;       To study and analyze the cognitive status like attention, language, memory and      
lobar function in patients with chronic kidney disease before and after renal transplantation 
 Materials and methods; This study was conducted from May 2012 to January 2014, 
Prospective study between May 2012 to January 2014, twenty five patients, Exclusion 
Criteria: Mentally retarded, Organic Psychosis, Patient on anti depression, had an absence of 
acute illness (e.g., metastatic cancer), neurological disease, and other major organ failure 
(e.g., end stage liver disease. Detailed history and neurological examination like mini mental 
state examination. Detailed lobar function, Addenbrooke’s cognitive examination-revised 
scale.Alzheimer's disease Cooperative Study (ADAS) - Cognitive Behavior. Wescthler 
Memory Scale will be done.  
 Details regarding the treatment will be obtained from history and treatment records. 
Analysis by standard method; Chi-Square Tests, student T test. 
Results; Among the cognitive function the executive function, Attention task, Anterograde 
memory, verbal fluency, and word recognition in memory function has been improved after 
renal transplant. . In memory function there is significant improvement in recall, Anterograde 
memory, verbal fluency, and word recognition after renal transplant, but there is no 
significant changes in the retrograde memory. No statically significant changes in language, 
the blood parameters are improved well. 
Conclusion; even the some of the cognitive domain is improved the further study in large 
groups in various cognitive domains and long term follow-up to determine the cognitive 
improvement. 
KEY words; ADAS score, renal transplant, cognitive level. 
Author;1. Resident in neurology, 2.professor of neurology, 3.professor of nephrology. 
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                                                 INTRODUCTION 
Renal disease is a gradually increasing common chronic illness affecting the 
middle and older adulthood. Chronic kidney disease affects 5-10% of the world 
population and is a universal health problem. When compared with the 
general population the prevalence of cognitive impairment is high in end stage 
renal disease (ESRD) 1,2. The overwhelming of cognitive impairment in chronic 
kidney disease and patients undergoing haemodialysis is noticeable only in the 
recent years. Severe cognitive impairment is synonymous in comparison to 
dementia.  DSM -V criteria duly states that dementia is a chronic cognitive 
impairment in two or more cognitive domains that substantially affects the 
daily function, representing a decline in the pre – morbid function and is not 
due to concomitant acute delirium. Though there is compromised cognition in 
patients undergoing dialysis, cumulative evidence shows that there is 
increased risk for cognitive difficulties in individuals even in the early course of 
the disease before the occurrence of renal failure. Having said that the 
cognitive performance following successful renal transplant is unclear, it is 
usually believed that the cognitive features return to pre-morbid levels after 
successful renal transplantation.  Short screening tests such as Mini Mental 
State Examination [MMSE] 3and 3MS –an adjunct of MMSE, which contains 
four added subtests, are applied to test cognitive impairment and a maximum 
2 
 
score of 100 points are given. On the whole these screening tests have limited 
sensitivity particularly for vascular cognitive impairment. So the prevalence of 
cognitive impairment in CKD 4,5 is still under estimated. In this study, the 
cognitive function in renal transplant recipient is assessed by various methods 
before and after [9 months] renal transplantation. The methods are: 
1] Mini Mental State Examination [MMSE] 
2] Higher mental functions and lobar functions 
3] Addenbrooke’s Cognitive Examination 
4] Wescthler Memory Scale 
5] Alzheimer’s Disease Cooperative Study - ADAS Cognitive                     
Behaviour 
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AIM OF THE STUDY 
       To study and analyze the cognitive status like attention, language, memory and      
lobar function in patients with chronic kidney disease before and after renal 
transplantation. 
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REVIEW OF LITERATURE 
Chronic kidney disease fringes a range of multifarious patho physiologic 
processes related to abnormal renal functions and a progressive deterioration 
in glomerular filtration rate (GFR). Stages of CKD depend upon GFR which is 
represented in the tabulation below. (Table -1) 
Table -1:  Classification of Chronic Kidney Disease (CKD) 6
 
a)  With risk factors for CKD. 
b) With demonstrated kidney damage (e.g., persistent proteinuria, 
abnormal urine sediment, abnormal blood and urine chemistry, 
abnormal image studies). 
      Abbreviation: GFR, glomerular filtration rate. 
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              Chronic renal failure (CRF) refers to the process of continuous, 
significant and irrevocable decrease in the number of nephrons which 
classically corresponds to the stages 3–5 of CKD. The term end-stage renal 
disease (ESRD) pertains to the stage of CKD in which there is accumulation of 
toxins, electrolytes and fluids that are normally excreted by the kidneys. The 
cumulative effect of these toxins results in uremic syndrome which is fatal. 
These uremic toxins are eliminated by Renal replacement therapy, using 
dialysis or renal transplant.  
Estimation of Glomerular Filtration Rate (GFR) is essential for the 
interpretation of stages of CKD. Parameters used are age, sex, body weight, 
race, serum Creatinine. The equations recommended for the calculation of GFR 
is as follows :( table-2) 
  Table 2: Recommended Equations for Estimation of Glomerular      Filtration 
Rate (GFR) Using Serum Creatinine Concentration (PCr), Age, Sex, Race and 
Body Weight 7,8 
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Leading categories of Etiologies of CKD: 
CKD being a universal health problem, several factors contribute to the 
aetiology of CKD (table-3). These factors vary according to different 
geographical region. Among those are five leading categories that account for 
more than 90% of CKD. 
 
Table - 3: Leading Categories of Etiologies of CKD 9 
 
 
 
CLINICAL ABNORMALITIES IN UREMIA 10 
Uraemia causes functional disturbances in all organ system producing various 
symptoms. 
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Fluid and Electrolyte Disturbances: 
 Volume expansion (I) 
 Hyponatremia (I) 
 Hyperkalemia (I) 
 Hyperphosphatemia (I) 
 
Endocrine-metabolic disturbances: 
 Secondary hyperparathyroidism (I or P) 
 Hyperuricemia (I or P) 
 Hypertriglyceridemia (I or P) 
 Increased Lp(a) level (P) 
 Decreased high-density lipoprotein level (P) 
 Protein-energy malnutrition (I or P) 
 Impaired growth and development (P) 
 Infertility and sexual dysfunction (P) 
 Amenorrhea (I/P) 
 β2-Microglobulin–associated amyloidosis (P or D) 
 
Neuromuscular disturbances: 
 Fatigue (I)b 
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 Sleep disorders (P) 
 Headache (P) 
 Impaired mentation (I)b 
 Lethargy (I)b 
 Asterixis (I) 
 Muscular irritability 
 Peripheral neuropathy (I or P 
 Restless legs syndrome (I or P) 
 Myoclonus (I) 
 Seizures (I or P) 
 Coma (I) 
 Muscle cramps (P or D) 
 Dialysis disequilibrium syndrome (D) 
 Myopathy (P or D) 
 
 
Cardiovascular and Pulmonary disturbances: 
 Arterial hypertension (I or P) 
 Accelerated atherosclerosis (P or D) 
 Hypotension and arrhythmias (D) 
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 Vascular calcification (P or D) 
Dermatologic disturbances 
Gastrointestinal disturbances 
Hematologic and immunologic disturbances 
Response to treatment modalities 
a)  After successful renal transplant there is complete reversal of all the 
above mentioned abnormalities.  
There is variable response to haemodialysis or peritoneal dialysis. 
(I) Symbolizes an optimal program of dialysis and related 
therapy. 
(P)  Indicates an abnormality that lasts, despite of an optimal program. 
(D) Signifies an abnormality that develops after the commencement of 
dialysis. 
b). Refines with erythropoietin and dialysis: 
          Abbreviation: LP (a), lipoprotein A. 
 
 CHARACTERISTICS OF COGNITIVE IMPAIRMENT IN CKD 
There is an increased association of end-stage renal disease (ESRD) with 
cognitive impairment. Recent data11 suggests that the probability of 
developing cognitive impairment and dementia is high among patients with 
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CKD (irrespective of the stage) than patients without CKD .There is a registered 
history of cognitive impairment only in 3% of patients. So further 
neuropsychological testing’s were done and proved that a higher prevalence 12 
of 87% of patients were subjected with mild to severe degree of cognitive 
impairment. 
Possible causes of cognitive impairment in patients with CKD  
1) Vascular Hypothesis 
2) Neurodegenerative Hypothesis       
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Illustration of the Probable causes of cognitive impairment in CKD 
patients (figure-2) 
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1) Vascular Hypothesis of cognitive impairment in patients with CKD. 
According to this hypothesis the brain and kidneys share many common 
features like anatomic and vaso regulation.  The end organs with low 
resistance are exposed to a larger volume of blood flow and are thus subjected 
to vascular damage 13. Hence the Tran cranial Doppler Ultrasonography is used 
for the evaluation of impaired cerebral hemodynamic 14. This provides 
fascinating information on the link between cognitive impairment and altered 
cerebro - vascular hemodynamic.  Previous Tran cranial Doppler 
Ultrasonography studies revealed a positive correlation between cognitive 
impairment and impaired hemodynamic, proposing that the micro vascular 
damage subscribes to the changes in cognitive that are identified in the early 
levels of dementia 15,16.  
Arterial hypertension being a major vascular risk factor contributes to 
cerebrovascular disease which plays an extensive role in the pathogenesis of 
impairment in cognitive functions in patients with CKD.  This explains the 
coalition between CKD and Cerebrovascular disease 17,18. Arterial hypertension 
is highly prevalent in patients with CKD than in others. 
Furthermore, the contribution of cerebral vascular lesions to cognitive 
impairment in CKD patients is supported by various hypotheses: 
13 
 
1)  It is suggested that the cause of cognitive   impairment is more due to   
vascular disease when compared to Alzheimer’s disease .An imparted data 
from the 3C study favours this hypothesis. The study showed that the faster 
decline in eGFR (follow-up during first 4-year period-0.4 ml/min per 1.73 m2) 
was proportional to global cognitive dysfunction and an episode of dementia 
comprising vascular component. 
2) The contribution is also supported by the notable decline in executive 
functions and the psychomotor speed similar to the picture in stroke 17. 
3) The pattern of cognitive disorders.                                                                                         
However, neuropathology studies revealed a wider dysfunction in cognition 
exists among patients suffering from small-vessel cerebrovascular disease 
including memory deficits. 
There is also a link between cognitive impairment and non-traditional 
vascular risk factors like inflammation, oxidative stress, and Hypercoagulable 
states and hyperhomocysteinemia 19. These factors speed up the process of 
atherosclerosis and vascular endothelial dysfunction 20,21. These twin factors 
are associated with risk of dementia. 
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HYPERHOMOCYSTEINEMIA AND COGNITIVE IMPAIRMENT 
Hyperhomocysteinemia is seen in 10% of general population and 85% in 
dialysis patient 23. According to a prospective cohort study, plasma 
homocysteine was found to be an independent risk factor for dementia 24. 
Elevated homocysteine levels leads to Cognitive impairment and this is 
explained by various mechanisms. 
1) Direct prothrombotic effect of hyperhomocysteinemia on the vascular 
system affects both large and small sized vessels 25. Increased levels of 
homocysteine provoke a direct   injury to the endothelium or stimulate 
an endothelial inflammatory response resulting in WML and its 
progression 26, 27. 
Hyperhomocysteinemia impairs neuronal pathways by direct, neurotoxic effect 
either by conversion into homocysteic acid or activating N-methyl-D–aspartate 
receptor which leads to cell death 28 . 
2) As per clinical studies there is an increased risk for Alzheimer disease  29 
in hyperhomocysteinemia. However reducing the levels of homocysteine 
in dementia patients does not lower the global cognitive decline 30 . 
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2) NEURODEGENERATIVE HYPOTHESIS OF COGNITIVE IMPAIRMENT 
There is high frequency of vasulopathy-related cognitive disorders in 
CKD patients but this can only be partly explained through brain abnormalities 
and vascular risk factors. So, other disease mechanisms are also involved. 
1) Chronic hypertension and other vascular risk factors share an 
increased risk for Alzheimer disease 31. 
 Conversely, the results of clinical trials and observational studies suggest that 
anti-hypertensive drugs lower the age-related dementia and cognitive decline, 
though longitudinal studies provide inconsistent findings 32. 
The Rotterdam study conducted in 2001 showed that there was only a 
lower risk for vascular dementia associated with anti hypertensive treatment. 
Another study Syst-Eur (the systolic hypertension in Europe) and Syst-Eur 2 
trials showed significant 50% reduction in the incidence of neurodegenerative 
and vascular dementia with anti hypertensive treatment.  
The studies 33 conducted during the past decade focused on the observation 
that the BP lowering activity of various anti hypertensive drugs had no 
correlation with the beneficial effects in preventing cognitive decline and 
dementia. 
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It has been suggested that Angiotensin Converting Enzyme (ACE) 
inhibitors might have adverse effect on cognition because ACE mediated 
conversion of Ab42 into Ab40.  
The Ab40 which is less amyloidogenic and also less toxic. Instead of ACE 
inhibitors the use of Angiotensin AT1-receptor blockers might endeavour a 
protective effect on cognition by activating AT2-receptors. 
Furthermore, Uremic toxin accumulation may induce a cerebral 
endothelial dysfunction and thus contributes to cognitive disorders in patients 
with CKD 34. Several Uremic toxins are implicated in the pathogenesis of 
cognitive impairment. However, it is still a dilemma that uremic toxins lead to 
cognitive impairment.  DeDeyn et al reported that levels of some guanidine 
compounds such as guanidine, methyl guanidine, Creatinine and 
guanidinosuccinic acid in the brain and cerebrospinal fluid are substantially 
elevated in uremic patients. High toxin concentration (up to 10 fold rise in CKD 
patients than in control) were found in the  brain regions such as thalamus, 
cerebral cortex and mammillary bodies that plays a determinant role in  
Cognition 35. The involvement of uremic guanidine compounds may be direct 
or indirect.  
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Studies in animals revealed that these guanidine compounds are 
neuroexcitatory agents and have convulsant activities. It can also have an 
indirect effect by favouring the elevation of serum homocysteine. Finally, Yaffe 
et al projected that community-resident elderly individuals who have increased 
levels of systatin-C (which is an inhibitor of cysteine proteases that binds with 
b-amyloid in the brain of Alzheimer disease patients) were found to have lower 
cognitive test scores and even after adjustment of vascular risk factors 
experienced a fall in cognitive function during a follow-up period of 7 years. In 
spite of the absence of MRI brain data’s, cystatin-C produces a direct effect on 
risk of developing Alzheimer disease. 
BRAIN IMAGING IN CKD PATIENTS 
Clinically evident stroke and subclinical cerebrovascular disease in patients 
with CKD 
A high prevalence of stroke is seen in patients with CKD.As per the U.S. Renal 
Data System, the prevalence of stroke among CKD patients are categorized as 
follows considering the age, sex and race 
          17%   -Long term haemodialysis patients 
10%   -Patients with mild to moderate CKD 
4%     -General population without CKD 
18 
 
The risk of dementia is doubled in both CKD and non-CKD populations with a 
previous history of stroke.  
Moreover, there is increased prevalence of subclinical cerebrovascular disease 
in CKD patients and manifests as silent brain infarcts, white matter lesions 
(WMLs), and cerebral infarcts with absent clinical symptoms and detected only 
by brain lesions with micro bleeds. Brain lesions in patients with CKD were first 
described in (CT) Computed Tomography-based studies .Passer et al reported 
over three decades that there was a prevalence of cerebral atrophy in CKD 
patients who underwent long term dialysis. It was proved that the lesions were 
prominent in the frontal lobes in such patients after correlation with duration 
of haemodialysis 36,37. 
SBIs in CKD  
Other risk factors have also been reported for cerebro vascular diseases 
like SBIs. Cusmano and Savazzi reported that around 10% of patients with CKD 
who were on haemodialysis had evidence of SBIs.  
At recent times it was found that a strong bond existed between eGFR 
and calcification of intracranial arteries in patients admitted with stroke or any 
other non vascular neuro logical disorders. There is an active and accelerated 
19 
 
process of vascular calcification in patients with CKD.MRI is largely used to 
detect subclinical manifestations of Cerebrovascular damage in these patients . 
The prevalence of SBIs is 8%-28% in normal individuals whereas it is 50% 
in advanced renal failure patients. SBIs are amalgamated with a higher 
incidence with stroke, incident dementia and decrease in cognitive function in 
CKD patients. The progressive worsening of GFR in patients with CKD revealed 
that SBI was an independent prognostic factor as illustrated in a prospective 
cohort study.  
WML in CKD 
There is increased prevalence of WML  38,39 (up to 70%)  in patients with  
stroke and in CKD patients.WMLs also indicate arteriosclerosis. Similar to SBIs 
=WMLs are also associated with high risk for dementia and stroke and have 
also proved to be fatal. Cross-sectional studies done on general population 
proved a strong link between volume and lesions of white matter with eGFR. In 
a multivariate statistical analysis, Martinez –Vea et al failed to prove the 
association between WMLs and vascular nephropathy. This absence puts 
forward the fact that increased number of WMLs in renal failure patients 
signifies systemic vascular disease.Sub Clinical Brain Lesion in CKD Imaging: 
(figure-3) 
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A) Magnetic resonance imaging (MRI) in axial fluid – attenuated 
inversion recovery showing silent brain lacunars infarct (arrow). 
B) Gradient – echo MRI imaging sequence showing micro bleed in 
multiple area located in right cerebral hemisphere (small foci of 
hypo intensity, arrow) 
C) Moderate & (D) Severe white matter lesions in the area of 
centrum ovale. 
21 
 
MATERIALS AND METHODS 
This study was conducted from May 2012 to January 2014. Patients were taken 
from department of nephrology in Rajiv Gandhi Government General hospital 
those who were enrolled for Renal Transplantation and undergone renal 
replacement replacement therapy. They were enrolled in this study after 
getting a written consent to analyses the cognitive status in chronic kidney 
disease patient before and after renal transplant, (6 to 9 months after renal 
transplant. 
 Design of the study duration of study: 
Prospective study between  May 2012 to January 2014, twenty five patients. 
Material/ selection of subjects: 
 1. Those who are admitted in nephrology ward for renal 
transplant between 10-60 years of age. 
Exclusion Criteria: 
 Mentally retarded  
 Organic Psychosis 
 Patient on anti depression 
22 
 
 Had an absence of acute illness (e.g., metastatic cancer), 
neurological disease, and other major organ failure (e.g., end 
stage liver disease).  
Methods/ Analysis: 
 Detailed history and neurological examination like mini mental 
state examination. 
 Detailed lobar function. 
 Addenbrooke’s cognitive examination-revised scale. 
 Alzheimer's disease Cooperative Study (ADAS) - Cognitive 
Behavior. 
 Wescthler Memory Scale will be done.  
 Details regarding the treatment will be obtained from history and 
treatment records. Analysis by standard method; Chi-Square Tests, student T 
test. 
Assessment of Parameter: 
The following clinical assessment will be made before and after renal 
transplant surgery. 
 Attention 
 Language 
23 
 
 Memory 
 Detailed lobar function.  
 Renal parameter, Blood pressure, heamoglbulin. 
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OBSERVATION AND RESULTS 
Totally 25 patients were enrolled in this study after getting a written consent 
to analyze the cognitive status in chronic kidney disease patient before and 
after renal transplant, (6 to 9 months after renal transplant) 
 
1. Age Distribution:  The minimum age enrolled was 17 years and 
maximum age was 49 years. Less than 30 years were 10 in numbers 30 – 
40 years 11 in numbers and more than 40 years were 23 in numbers. 
(Table-4, 5, Figure-4). 
 
Table 4 
Age in Years N Minimum Maximum Mean 
 
 
 
25 
 
17 
 
49 
 
32.52 
     
 
 
 
25 
 
 
Table 5 
Age No. of patients 
< 30 years 10 
30 to 40 years 11 
>40 years 4 
 
 
 
 
10
11
4
Figure 4
Age Distribution
Less than 30 yrs
30 - 40 yrs
More than 40 yrs
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2. Sex Distribution: In this study, out of 25patients 20 (80%) were males and 
5(20%) were females (Table-6 and Figure-5). 
 
Table 6 
Sex Distribution Frequency Percent Valid Percent 
 Male 20 80.0 80.0 
  Female 5 20.0 20.0 
  Total 25 100.0 100.0 
 
   
 
 
 
 
20
5
Figure 5
Sex Distribution
Male - 20
Female - 5
Total - 25
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3. Kidney Donor:  
Total number of patients is 25, cadaveric kidney was used in 11   patients 
(44%) and live donor kidney was used in 14 patients (56%). 
     (Table-7 and Figure-6). 
            
           
 
        
 
           
  
                
 
11
14
0
5
10
15
Cadaver kidney Live donor kidney
Figure 6
No. of patients - 25
Cadaver kidney
Live donor kidney
Table 7 
Kidney Donor Frequency Percent 
Cadaver 
Live 
Total 
11 44.0 
14 56.0 
25 100.0 
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4. Haemoglobin Level - Before and after in transplant (gm %) 
    The mean Hb before RT was 8.44 and some of the patients were received 
injection Erythropoietin before surgery. The mean Hb after RT was 11.564 
and there is significant p value (0.000) (Table-8and Figure-7). 
 
Table -8 
Haemoglobin Level 
l (gm %) Mean N 
Std. 
Deviation P value 
 
1 
Haemoglobin(%) 
before RT 
8.440 25 .3291 
0.000 
  
        2 
Haemoglobin(%) 
after RT 
11.564 25 .7799 
             
:  
8.44
11.564
0
5
10
15
Before RT After RT
Figure-7  : Heamoglobin  Level  gm%-
Mean
Before RT
After RT
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5. Blood Urea Level -   Before & After RT  
    The  mean blood urea level before RT was 115.60 and the mean  blood urea 
level after RT was 31.60 there is significant p value(0.000) was noted  (Table-
9 and Figure-8).           
 
 
:  
0
20
40
60
80
100
120
Before RT After RT
115.6
31.6
Figure-8:  Blood urea level - Mean
Before RT
After RT
Table-9 
 
Blood urea level (mg %) 
 
Mean 
 
N 
 
Std.Deviation 
 
P value 
1 Blood urea before 
RT(mgs) 
115.600 25 21.5948 
0.000 
2 Blood urea after 
RT(mgs) 
31.600 25 6.4291 
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6. Serum Creatinine – Before & After RT  
The mean serum Creatinine level before RT was 8.108 and the mean serum 
creatinine level after RT was 1.300 and there is significant p value(0.000) 
was noted . (Table-10 and Figure-9).               
 
 
 
0
2
4
6
8
10
Before RT After RT
8.108
1.3
Figure -9 :  Serum  creatinine  (mgs%)  -
Mean
Before RT
After RT
Table-10 
 
Serum Creatine level (mg %) 
 
Mean 
 
N 
 
Std.Deviation 
 
P value 
 
1 
Serum Creatine  
level  before RT 
8.108 25 1.7628 
0.000 
 
2 
Serum Creatine  
level after RT 
1.300 25 0.3227 
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7. Systolic BP – Before & After RT : 
 The mean systolic BP level before RT was 142.40 and the mean systolic BP 
level after RT was 123.6 and there is significant p value(0.000) was noted. 
(Table-11 and Figure-10).             
          
 
 
 
110
120
130
140
150
Before RT After RT142.4
123.6
Figure -10:  Systolic BP Level (mm of hg) 
- Mean
Before RT
After RT
Table -11 
 
Systolic BP  level (mm of hg) 
 
Mean 
 
N 
 
Std.Deviation 
 
P value 
 
1 
Systolic BP  level  
before RT 
142.40 25 31.262 
0.005 
 
2 
Serum Creatine  
level after RT 
123.60 25 10.755 
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8. Diastolic BP – Before & After RT: 
The mean diastolic BP level before RT was 90 and the mean diastolic BP level 
after RT was 80.40 and there is significant p value (0.000) was noted. (Table-
12 and Figure-11) 
 
 
  
90
80.4
74
76
78
80
82
84
86
88
90
92
Before RT After RT
Figure-11: Diastolic BP - Mean
Before RT
After RT
Table-12 
 
Diastolic BP  level (mm 
of hg) 
 
Mean 
 
N 
 
Std.Deviation 
 
P 
value 
 
1 
Diastolic BP  level 
before RT 
90 25 9.129 
0.000 
 
2 
Diastolic BP  level 
after RT 
80.40 25 5.385 
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9 .Duration of Dialysis before RT (in months)  
 The duration of dialysis varied from 1 month to 10 months depends             
upon the availability of kidney donor. (Table-13 and Figure-12). 
   
               
 
 
 
12
11
2
Figure-12
No. of patients - 25
< 3 months of dialysis
3-6 months of dialysis
>6 months of dialysis
Table-13 
Period of dialysis Frequency Percent 
  
  
  
< 3 12 48.0 
3-6 11 44.0 
> 6 2 8.0 
Total 25 100.0 
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10. Mini Mental State Examination ( MMSE): 
Mini mental State Examination (MMSE) was conducted in all patients 
before and after RT and the mean difference was not statistically 
significant. (Table-14 and Figure-13). 
              
 
 
26
27
28
29
30
Before RT After RT
27.48 27.72
Figure- 13
MMSE - Mean
Before RT
After RT
Table-14 
MMSE Mean N 
Std. 
Deviation 
P Value 
 
MMSE before RT maximum 
score 30 
27.48 25 1.262 
.110 
MMSE after RT maximum 
score 30 
27.72 25 1.021 
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11. Attention & Orientation: 
 The attention and orientation task was performed with ADAS scoring there 
was significant mean value which was statistically significant (Table-15). 
 
Table-15 
Attention & Orientation 
Me
an 
N 
Std. 
Deviation 
P value 
  Attention & Orientation - 
15 pts before RT 
13.4
8 
25 .586 
0.000 
Attention & Orientation - 
15 pts after RT 
13.8
8 
25 .526 
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12. Number of Errors in Maze Test: 
 The maze test was used as Executive Function to test the sequence of test 
and time of completion, there is significant p value was noted  in number of 
error and time of completion. (Table-16 and Figure-14). 
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Figure-14
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Number of Errors before RT
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Table-16 
Number of Errors Mean N 
Std. 
Deviation P value 
 Number of 
Errors before RT 
.12 25 .332 
0.001 
  Number of 
Errors  after RT 
.00 25 .000 
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13. Time at Completion in maze test: (Table-17 and Figure-15). 
 
Table-17 
Time at completion Mean N 
Std. 
Deviation 
P 
value 
Time at completion 
in sec before RT 
11.00 25 1.528 
0.000 
Time of completion 
in sec after RT 
8.84 25 1.375 
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Time at completion in sec 
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Time of completion in sec 
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14. Constructional Praxis Before RT and After RT : Chi-Square Tests 
The constructional praxis was tested with circle. Two overlapping rectangles 
Rhombus Cube and there is significant improvement noted with constructional 
praxis before and after RT was noted. (Table-18  ).           
           
Table-18 
  
Constructional 
Praxis after RT Total 
P 
value 
  Normal Abnormal  
Constructional 
Praxis before 
RT 
 
 
 
Normal Count 20 0 20 
0.000 
 
  % within 
Constructional 
Praxis before 
RT 
100.0% .0% 100.0% 
  % within 
Constructional 
Praxis after RT 
90.9% .0% 80.0% 
Abnormal Count 2 3 5 
    % within 
Constructional 
Praxis before 
RT 
40.0% 60.0% 100.0% 
    % within 
Constructional 
Praxis after RT 
9.1% 100.0% 20.0% 
Total Count 22 3 25 
  % within 
Constructional 
Praxis before 
RT 
88.0% 12.0% 100.0% 
  % within 
Constructional 
Praxis after RT 
100.0% 100.0% 100.0% 
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15. Ideational Praxis Before & After RT: 
There is no statistically significant ideational praxis noted before and after  
RT. (Table-19 and Figure-16). 
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Figure-16 : Ideational Praxis before & after 
RT
Ideational Praxis 
before & after RT
Table-19 
Ideational 
Praxis 
Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
 Normal 25 100.0 100.0 100.0 
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16. Memory Testing Before & After RT: 
Memory was tested with following test. There is significant p value noted 
in recall test.  (Table-20and Figure-17). 
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Figure-17 :Memory Before &  After RT   
Word  Recall maximum  3  points
Recall before RT 
Recall after RT  
Table-20 
Recall Mean N 
Std. 
Deviation 
P Value 
 Recall before RT 
max 3 points 
2.44 25 .651 
0.001 
  Recall after RT  
max 3 points 
2.80 25 .408 
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17. Anterograde Memory Before & After RT: 
Memory was tested with a name and address and ask them to repeat the 
words, significant p value was noted after renal transplantation. 
 (Table-21 and Figure-18)  
 
 
0
1
2
3
4
5
6
7
before RT after RT
4.12 4.56
Figure-18 : Anterograde  memory  Before & 
After RT Maximum 7 points
before RT
after RT
Table-21 
 Mean N 
Std. 
Deviation 
P value 
 
Anterograde max points 
= 7 before RT 
4.12 25 .726 
. 
0.000 Anterograde max points 
= 7 after RT 
4.56 25 .768 
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18. Delayed Recall Before & After RT: 
Delayed memory was tested with a name and address and ask them to 
repeat the words, significant p value was noted after renal transplantation. 
(Table-22). 
 
 
Table-22 
Delayed Recall Mean N 
Std. 
Deviation 
P Value 
 
Delayed Recall max 7 
points before  RT 
3.32 25 .900 
0.000 
Delayed recall after RT 3.80 25 .913 
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19. Retrograde Before & After RT: 
There is no significant p value noted when tested with retrograde memory 
(name of the chief minister or prime minister. (Table-23 & Figure-19).            
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19. Retrograde Before & 
After RT Maximum 4 Points
Table-23 
 Mean N 
Std. 
Deviation 
P Value 
 
Retrograde max 4 
points before RT 
2.72 25 .843 
0.022 
 
Retrograde max 4 
points after RT 
2.92 25 .759 
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20. Word Recognition Before & After RT: 
Word recognition was tested with 10 words and noted significant p value 
noted after RT. (Table-24 and Figure-20).             
Table-24 
Word Recognition Mean N 
Std. 
Deviation 
P Value 
 Word Recognition 
before RT" 
5.88 25 1.013 
0.001 
  Word Recognition 
after RT" 
6.28 25 1.137 
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VERBAL FLUENCY TESTING: 
21. Animals/mt before & After RT: 
Animals /mt were tested with each patients and noted significant p value 
noted after RT. (Table-25and Figure-21). 
Table-25 
Animals Mean N 
Std. 
Deviation 
P Value 
 
Animals/mt before 
RT max 7 points 
3.24 25 .831 
0.000 
Animals/mt after RT 
max points 7 
4.08 25 1.038 
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22. Words/mt before & After RT: 
  FAS test (words/mt) was tested with each patients and noted significant p 
value noted after RT. (Table-26and Figure-22). 
          Table-26 
Words Mean N Std. Deviation P Value 
 
Words/mt before RT max 7 point 3.48 25 .714 
0.000 
Words/mt after RT max 7 points 4.28 25 .980 
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22. Comprehension writing Repetition, Naming, Reading before & After 
RT:             (Table-27 and Figure-23). 
Table-27 
   
Comprehension 
writing before RT Total 
    Normal   
Comprehen
sion       
writing 
before RT 
Normal Count 
25 25 
    % within 
Comprehension 
writing before RT 
100.0% 100.0% 
    % within 
Comprehension 
writing before RT 
100.0% 100.0% 
Total Count 25 25 
  % within 
Comprehension 
writing before RT 
100.0% 100.0% 
  % within 
Comprehension 
writing before RT 
100.0% 100.0% 
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Comprehension and Writing
Comprehension and 
Writing
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23. Visuospatial Ability before RT * Visuospatial Ability after RT 
Crosstabulation 
Visuospatial ability before RT and after RT was tested with copying cube, circle, 
draw a clock face with the numbers on it and there is no significant p value was 
noted. (Table-28and Figure-24). 
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Table-28 
   
Visuospatial Ability 
after RT Total 
P value 
    Normal Abnormal   
Pearson 
Chi-
Square 
Visuo-
spatial 
Ability 
before 
RT 
  
  
  
  
  
Normal 
  
Count 21 0 21  
% within 
Visuospatial 
Ability before 
RT 
100.0% .0% 100.0% 
.019 
  % within 
Visuospatial 
Ability after RT 
87.5% .0% 84.0% 
 
Abnormal 
  
  
Count 3 1 4  
% within 
Visuospatial 
Ability before 
RT 
75.0% 25.0% 100.0% 
 
% within 
Visuospatial 
Ability after RT 
12.5% 100.0% 16.0% 
 
Total Count 24 1 25  
  % within 
Visuospatial 
Ability before 
RT 
96.0% 4.0% 100.0% 
 
  % within 
Visuospatial 
Ability after RT 
100.0% 100.0% 100.0% 
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24. Perceptual Ability before RT * Perceptual Ability after Identifying letters 
RT 
Perceptual ability was noted with Counting dots, it and there is no significant p 
value was noted (Table-29 and Figure-25). 
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Table-29 
   
Perceptual 
Ability after RT Total 
    Normal   
Perceptual 
Ability 
before RT 
Normal Count 
25 25 
    % within 
Perceptual 
Ability before 
RT 
100.0% 100.0% 
    % within 
Perceptual 
Ability after RT 
100.0% 100.0% 
Total Count 25 25 
 % within 
Perceptual 
Ability before 
RT 
100.0% 100.0% 
  % within 
Perceptual 
Ability after RT 
100.0% 100.0% 
 
 
 
 
  
52 
 
25. Copying before RT * Copying after RT table-30  Figure-26 
       Copying was tested and there is no significant p value noted.  
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Table-30 
   Copying after RT Total P value 
   Normal 
Abnor
mal   
 
Pearso
n Chi-
Square 
Copying 
before RT 
Normal Count 
20 0 
  
    % within 
Copying 
before RT 
100.0% .0% 100.0% 
.041 
    % within 
Copying 
after RT 
83.3% .0% 80.0% 
 
  Abnormal Count 4 1 5  
    % within 
Copying 
before RT 
80.0% 20.0% 100.0% 
 
    % within 
Copying 
after RT 
16.7% 100.0% 20.0% 
 
Total Count 24 1 25  
  % within 
Copying 
before RT 
96.0% 4.0% 100.0% 
 
  % within 
Copying 
after RT 
100.0% 100.0% 100.0% 
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DISCUSSION 
Totally 25 patients were enrolled in this study after getting a written consent 
to analyze the cognitive status in chronic kidney disease patient before and 
after renal transplant, (6 to 9 months after renal transplant). 
Age Distribution:  
        The minimum age enrolled was 17 years and maximum age was 49 years. 
4 patients were more than 40 years.  
Sex Distribution:   
            In this study, out of 25patients 20 (80%) were males and 5(20%) were 
females.  
Haemoglobin Level:  
        The mean Hb before RT was 8.44 gms and some of the patients received 
injection Erythropoietin before surgery. The mean Hb after RT was 11.564 gms 
and significant p value (0.000) was noted .There is significant increase in 
haemoglobin level   after RT. Usually the Hb improved significantly by 3 months 
after RT. This corresponds to Iwamoto H 40 (Iwamoto et al., 2014), Nakumura 
et al study, Montanaro et al study 41.  
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Blood Urea Level:  
The  mean blood urea level before RT was 115.60  mgs and the mean  blood 
urea level after RT was 31.60 mgs there is significant notable p value(0.000) 
.This is correlated with the Reinhardt.w. et al  42 study in post renal transplant  
that there is significant reduction in blood urea level except in few patients 
with impaired graft function. 
Serum Creatinine:  
The mean serum Creatinine level before RT was 8.108 mgs  and the mean 
serum  Creatinine  level after RT was 1.300mgs  and  there is significant p 
value(0.000) was noted. This is correlated with the Reinhardt.w. et al  42  
study in post renal transplant there is significant reduction in serum 
Creatinine level except in few patients with impaired graft function. 
 Blood pressure:  
 The mean systolic BP level before RT was 142.40 mm of Hg and the mean 
systolic BP level after RT was 123.6 mm of Hg and there is significant p value 
(0.000) noted .The mean diastolic BP level before RT was 90 mm of Hg and 
the mean diastolic BP level after RT was 80.40  mm of Hg and there is 
significant p value (0.000)  noted. There is significant reduction in the  BP 
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after RT about 30% patient taking regular anti HT drugs even after RT ,this is 
correlated with previous pilot study( Saxena Anita, Sharma R K etal) 43 
Duration of Dialysis before RT ; 
The duration of dialysis varied from 1 month to 10 months depends             
upon the availability of kidney donor.  
Cognitive function compromise has been reported by Techan et al 44 Qurella 
Chertow, Luan and Yaffe Etal. It depends upon underlying dialysis treatment 
duration. 
 Earlier, ESRD patients who underwent haemodialysis procedure 
continuously may lead to cognitive impairment which is known as   Dialysis – 
Associated Dementia. This was first noted by Alfrey, LeGendre and Kaehny 
Etal.45 This dialysis associated dementia could be most often prevented by 
using water purification technique, thereby preventing aluminium toxicity. 
(Burn and Bates 1998).46 .Haemodialysis result in decreased cerebral blood 
flow and changes in haemotocrit level and other co –morbid Cerebrovascular 
disease associated with cognitive compromise.( Lass & Colleagues et al 1999).47 
Various studies was  performed on attention during dialysis. 
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COGNITIVE ASSESSMENT: 
Executive Function:  
Poor executive function has been improved in RT patients when compared to 
patient on dialysis. This correlates with previous study by Smith, A. (1973) et al 
48 and Matthews, C. G., & Klove, H. (1964) 49. In above study executive function 
tested by trail making test, simple digit modality test and written test .In both 
studies, the extent of residual cognition that are present in early CKD is not 
mentioned which may persist following renal transplantation. . In our study, 
the executive function has been tested by maze test (Number of error , Time of 
completion) , Stroop test, Trail making test resulting in statistically significant 
value noted after renal transplantation by  the means of  less number of error 
and less time of completion.  
 
Attention: 
                      Uchida etal  50 studied the performance of attention both before 
and after successful renal transplant compared to the person on dialysis in 
1951 by Uchida – Kraepelin continuous simple addition test.51. Two longitudinal 
studies has been conducted for attention by Takuma et al 51 and Krarner et al 
using an attention task (Trails A) and a cognitive screening measure (MMSE). 
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The transplant participants were tested prior to RT and 9-19 months after 
renal transplantation. Post RT performance improved compared to pre RT 
performance but not at the level of significance. 
                 While these findings provide some support that few domains of 
cognition (memory &attention) improve from the state of failure to the state 
of renal compensation (Post RT). The research does not mention to what 
extent reduced cognitive performance that present in early CKD may persist 
following RT.  
1. Mattews & Klove et al  49 across sectional comparison suggest that 
improvement of attention and memory but not in executive function 
following RT. Grivia et al found that there was  improvement in attention 
for RT in comparative dialysis participant (transplant patients showed 
32% improvement on simple addition test in second visit) but it was not 
statistically significant.  There is no available data to compare the 
cognition in early CKD and post RT. 
2.  In our study attention was tested with digit forward, digit backward, 
spell backward, simple calculation, Go-no-go test, and Vigilance test. The 
results showed significant p value (.000) in our study as compared to 
Uchida etal, Mattews & Klove et al. 
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Memory: 
 The important question concerned is that whether the renal transplantation 
improves one to state of pre-morbid baseline cognition ability. For this 
question, one must compare the performance of renal RT patients to that of 
healthy controls. 
 The griva et al study (2004)  52 showed the memory remains equivocal after 
RT.Bermond et al study (2005) 53 indicating the poorer memory after RT but 
lack of study control group. The small size renal RT participants and the control 
group stated the null difference noted in the study. 
Delis –Kaplan 54 executive function system stated that the cognitive function 
was not found to relate with severity of CKD like Hb level, estimated GFR, the 
stages of kidney disease and depression was noted.Pliskin, Kiolbasa et al 
mentioned the co morbid condition like diabetes, HT, CAD and depressive 
illness may contribute to cognitive worsening in CKD even after the successful 
RT. 
There is  general belief that cognitive function will improve after successful RT, 
but there is no evidence to support this. so, many studies was conducted in 
children with successful RT like fennel et al Morris et al  stated there is no clear 
evidence finding in children. 
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Saan& deelman, 1998  55 evaluate the verbal memory task was compared with 
normal data and RT patient’s worse on verbal memory in RT patients. 
Bemund et al evaluate the memory in RT patients. The author found that high 
dose of predinsolone were associated with memory defect like immediate 
recall, delayed recall, abstract and concrete  .This effect particularly due to 
long term usage of predinsolone leads to increase level of steroids receptors in 
the hippocampus, this may be related with poor memory function. 
                  In this study there is significant  p value noted in recall (three words), 
Anterograde memory (name and address) , Delayed Recall, verbal fluency (FAS 
test-words/mt, animals/ mt) word recognition, but the retrograde 
memory(personal events, family events, name of the  prime minister’s, the 
woman who was Prime Minister etc) is not significantly  improved. 
Language; 
The language was tested with Comprehension, writing, repeation; naming, 
reading perceptual abilities (identifying dots, numbers, and letters).There is no 
statistically significant changes noted in this study. A visuospatial ability (Circle, 
Numbers, Hands) was tested .there is significant changes after RT in statistical 
analysis. 
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CONCLUSION 
1. In this study the cognitive function was assessed in renal transplant 
receptions before and after surgery with various methods in 25 patients. 
2. Among the cognitive function the executive function, Attention task, 
Anterograde memory, verbal fluency, and word recognition in memory 
function has been improved after renal transplant. 
3. Attention was tested with digit forward, digit backward, spell backward, 
simple calculation, Go-no-go test, and Vigilance test, the results showed 
stastically significant p value in our study.  
5. In memory function there is significant improvement in recall, anterograde 
memory, verbal fluency, and word recognition after renal transplant, but there 
is no significant changes in the retrograde memory. 
6. In language domain Comprehension, writing, repeation, naming, reading 
perceptual abilities (identifying dots, numbers, and letters) there is no 
statistically significant changes noted before and after renal transplant in this 
study. 
7. There is stastically significant value noted in biochemical parameter like 
improvement in hemoglobin level, serum Creatinine level decline, blood urea 
level decline, blood pressure control after the renal transplant. 
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The sample size was small and needs to study in large groups in various 
cognitive domains and long term follow-up to determine the cognitive 
improvement. 
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ABBREVIATIONS 
RT- renal transplant 
CKD- chronic kidney disease 
ESRD-    end stage renal disease  
CAD- coronary Artery disease 
MMSE- Mini Mental State Examination  
ADAS-Alzheimer’s Disease Cooperative Study  
GFR-glomerular filtration rate  
ACE-Angiotensin Converting Enzyme  
WMLs-white matter lesions (WMLs) 
SLB-silent brain infarcts 
MRI-Magnetic resonance imaging  
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               To study and analyses the cognitive profile in                                                                                                                   
chronic kidney disease patient before and         
After renal transplant’’.                         
 
 
 
Name:                                                                                            Date: 
Age/Sex:                                                       OP/IP No: 
Weight:             MIN No: 
Occupation:                                                                           DOA; 
Mother Tongue: 
Income:                                                                                  DOS; 
                                                                                                DOD; 
Address:                                                                               donor    1.live;                                                                                                        
a. Relative                                                                                            A. relative 
Phone number:                                                                                  B. Spouse 
Educational status:                                                                           2.Cadaver 
Biopsy report; 
Drug protocol; 
Clinical Examination: 
1. Mini Mental State Examination 
2. Detailed Lobar function 
3. Addenbrooke’s Cognitive Examination 
4. Wescthler Memory Scale 
5. ADAS- Cognitive Behavior 
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